Chimeric antigen receptor T cell therapy (CAR-T cell) - guidelines for costing, counting and reconciliation of funding

Date published: 18 June 2020

The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.

Is this page useful?

Was this page useful?

Help us improve your IHACPA experience.

Help us improve ihacpa.gov.au

Thank you for taking the time to provide feedback for this page. If your enquiry is about something more specific, please visit our Contact page.